Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | Director · President and CEO | January 08, 2019 | January 10, 2019 |
| GENOCEA BIOSCIENCES, INC.GNCA · Entity 12635 | Director | July 01, 2021 | July 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date January 08, 2019 · Filed January 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,204,966 |
Reported balance
After 2019-01-08 transaction · row 1
1 source rowRow 1 · 2019-01-08 · Sale · Disposed 12,000 · Balance 1,204,966 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F2: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.83. The price reported above reflected the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended.
F2: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.83. The price reported above reflected the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
GENOCEA BIOSCIENCES, INC.
Report date July 01, 2021 · Filed July 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.33 · Expires 2031-07-01 | Direct | 15,000 |
Reported balance
After 2021-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-01 · Grant · Acquired 15,000 · Balance 15,000 F1: 100% of the options are scheduled to vest on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the options are scheduled to vest on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2017 Filed Sep 6, 2017 17:05 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 200 | $21.20 | $4,239.00 |
DisclosureSEC source: 0001179110-17-012109 · edgar.xml · nonDerivative · entry 2 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,414,429 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $21.13 to $21.26. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 17:05 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 9,800 | $20.40 | $199,911.18 |
DisclosureSEC source: 0001179110-17-012109 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,414,629 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.09 to $21.06. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 11, 2017 Filed Aug 14, 2017 16:35 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 6,666 | $20.02 | $133,449.99 |
DisclosureSEC source: 0001179110-17-011453 · edgar.xml · nonDerivative · entry 2 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,424,429 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 16:35 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 10,000 | $20.02 | $200,160.00 |
DisclosureSEC source: 0001179110-17-011453 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,431,095 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 16:53 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $5.34 Strike: $5.34 | $80,100.00 |
DisclosureSEC source: 0001592469-17-000002 · wf-form4_149756000015775.xml · derivative · entry 1 Bosley Katrine · CIK 0001592469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-13 F1 · derivative.exercise_date: The option vests 100% on the first anniversary of the grant date. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 13:15 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 312,000 | $0.00 Strike: $24.60 | $0.00 |
DisclosureSEC source: 0001179110-17-003790 · edgar.xml · derivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,000 Underlying: Common Stock · 312,000 shares Expires 2027-02-28 F1 · derivative.exercise_date: This option was granted on March 1, 2017 and is scheduled to vest over four years in equal monthly installments beginning on March 1, 2017 through March 1, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.